Assurance Infusion Recalls BUP 4MG/FENT 3000MCG/ML Injection Due to Sterility Concerns
Assurance Infusion is recalling BUP 4MG/FENT 3000MCG/ML Injection in 20 mL syringes due to a lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving potential hospitalization or significant injury risks associated with sterility failures in injectable drugs.
Plain-English summary
Assurance Infusion is recalling BUP 4MG/FENT 3000MCG/ML Injection in 20 mL syringes. The recall was initiated due to a lack of sterility assurance. The affected product is identified by Lot 12182019@7 with an expiration date of 12/27/2019.
The product was distributed nationwide within the United States. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers should stop using the affected product and contact Assurance Infusion at (713) 533-8800 for further instructions or a refund.
The recalled product
- Product
- BUP 4MG/FENT 3000MCG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800
- Manufacturer
- Assurance Infusion
- Category
- Drug — Injectable
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lots: 12182019@7 Exp. 12/27/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 118 recalled by Assurance Infusion under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 118 products in this recall →Related recalls
Same manufacturer · Assurance Infusion
See all →- SevereAssurance Infusion Recalls Buprenorphine and Hydromorphone Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Hydromorphone Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Fentanyl Syringes Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Morphine Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Buprenorphine and Morphine Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- SevereInfusion Options Recalls Mitomycin Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereDeferoxamine Injection Syringes Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2016-06-08
- SevereInfliximab Infusion Bags Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Avastin Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- HighNeostigmine Methylsulfate Injection recalled due to sterility assurance failure
FDA (Drugs) · 2022-07-27
- SevereInfusion Options Recalls Injectafer IV Products Due to Sterility Concerns
FDA (Drugs) · 2019-08-21